North America Cancer Supportive Care Products Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2021 –2028 |
 Marktgröße (Basisjahr) | USD 11,043.65 Million |
 Marktgröße (Prognosejahr) | USD 15,822.55 Million |
 CAGR |
% |
| Wichtige Marktteilnehmer |
North America Cancer Supportive Care Products Market, By Drug Type (Granulocyte Colony Stimulating Factor (GCSFs), Erythropoietin Stimulating Agents (ESA’S), Opioid Analgesics, Monoclonal Antibodies, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Bisphosphonates, Anti-Emetics, Antihistamines and Others), Type (Branded and Generics), Cancer Type (Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukaemia, Melanoma, Ovarian Cancer and Other Cancers), End User (Hospitals, Clinics, Hospitals & Academic Institutions and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Compounding Pharmacies), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2028
Market Analysis and Insights: North America Cancer Supportive Care Products Market
The cancer supportive care products market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.7% in the forecast period of 2021 to 2028 and is expected to reach USD 15,822.55 million by 2028 from USD 11,043.65 million in 2020. Increasing usage of cancer supportive care products, growing incidence of cancer disease are the major drivers which propelled the demand of the market in the forecast period.
The cancer supportive care products are the drugs administer during the cancer treatment to improve the health quality of patients. Cancer supportive care products are essential during the cancer chemotherapy treatment as the cancer treatment is associated with severe side effects. Cancer supportive care products are given to the patients to relieve, manage or prevent the adverse effects and accelerate the patient’s comfort during the cancer treatment.
The growing cancer patient pool burden in developed as well as developing country is anticipated to accelerate the demand of cancer supportive care products. Consequently, it will help to bolster up the cancer supportive care products market growth. It is predicted that high prevalence and disease burden of cancer is a major driving factor for the growth of the cancer supportive care products market. The increasing side effects of cancer supportive care medication are acting as a restraint for hampering the demand of the cancer supportive care products market.
The agreement and acquisition is the golden opportunity for the cancer supportive care products market players to elevate their revenue growth. The development of newer versions of the drug could significantly change the compound from the original compound. This approach may also lead to new clinical trials and patent re-applications so the drug's patent expiration is acting as a challenge for the cancer supportive care products market.
The cancer supportive care products market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the cancer supportive care products market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Cancer Supportive Care Products Market Scope and Market Size
The cancer supportive care products market is categorized into five notable segments which are based on drug type, type, cancer type, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of drug type, the cancer supportive care products market is segmented into granulocyte colony stimulating factor (GCSFs), erythropoietin stimulating agents (ESA’s), opioid analgesics, monoclonal antibodies, nonsteroidal anti-inflammatory drugs (NSAIDs), bisphosphonates, anti-emetics, antihistamines and others. In 2021, granulocyte colony stimulating factor (GCSFs) segment is dominating the cancer supportive care products market as it stimulates the bone marrow and generates stem cells as well as granulocytes to discharge it in bloodstream. Moreover, granulocyte colony stimulating factor (GCSFS) is primarily used to treat and cure the neutropenia caused owing to cancer chemotherapy treatment.
- On the basis of type, the cancer supportive care products market is segmented into branded and generics. In 2021, generics segment is dominating the cancer supportive care products market since it is cost effective, easily accessible and primarily recommended by doctors for cancer supportive care products diseases.
- On the basis of cancer type, the cancer supportive care products market is segmented into lung cancer, breast cancer, prostate cancer, liver cancer, bladder cancer, leukaemia, melanoma, ovarian cancer and other cancers. In 2021, the lung cancer segment is dominating the cancer supportive care products market due to growing smoking habits among populace in developed as well as developing country.
- On the basis of end user, the cancer supportive care products market is segmented into hospitals, clinics, hospitals & academic institutions and others. In 2021, hospitals segment is dominating the cancer supportive care products market as it provides patients with the best healthcare services. Moreover, hospitals are the primary healthcare service provider for patients suffering from cancer.
- On the basis of distribution channel, the cancer supportive care products market is segmented into hospital pharmacies, retail pharmacies and compounding pharmacies. In 2021, hospital pharmacies segment is dominating the cancer supportive care products market as most of the medicines are procured through hospital pharmacies. The increasing adoption of prescription based medicines, also acts as driver for the cancer supportive care products market growth.
Cancer Supportive Care Products Market Country Level Analysis
The cancer supportive care products market is analysed and market size information is provided by country, drug type, type, cancer type, end user and distribution channel as referenced above.
The countries covered in North America cancer supportive care products market are U.S., Canada and Mexico.
North America is expected to dominate the market due to the high adoption of cancer supportive care products by the patients in the region. The U.S is dominating in the market and leading the growth in the North America due to increased presence of key market players in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Strategic Initiatives by Manufacturers is Creating New Opportunities for Players in the Cancer Supportive Care Products Market
Cancer supportive care products Market also provides you with detailed market analysis for every country growth. Additionally, it provides data regarding acquisition and agreement among the major market plyers and start-up companies. Moreover, growing impact of research and development activities on cancer supportive care products increases market growth pace. The data is available for historic period 2010 to 2019.
Competitive Landscape and Cancer Supportive Care Products Market Share Analysis
The cancer supportive care products market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to cancer supportive care products market.
The major players covered in the report Amgen Inc., Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.), Pfizer Inc., APR, Novartis AG, F. Hoffmann-La Roche Ltd., Acacia Pharma Group Plc., Baxter, Bayer AG, Helsinn Healthcare SA., Heron Therapeutics, Inc., Kyowa Kirin Co., Ltd., Acrotech Biopharma, Spectrum Pharmaceuticals, Inc., Oxford Pharmascience Ltd, Merck Sharp & Dohme Corp. (A Subsidiary of Merck & Co., Inc.), Teva (A Subsidiary of Teva Pharmaceutical Industries Ltd.), Tersera Therapeutics Llc., Mylan N.V., Sun Pharmaceutical Industries Ltd., other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product approval and agreement are also initiated by the companies’ worldwide which are also accelerating the cancer supportive care products market.
For instance,
- In January 2020, Novartis AG declared the acquisition with the Medicines Company. This acquisition has provided novel opportunity to the company to escalate its geographical presence across the world as well as it has helped in upgrading the product portfolio of the company.
- In October 2019, Heron Therapeutics, Inc. announced the U.S. Food and Drug Administration approval of Heron's supplemental New Drug Application (sNDA) for CINVANTI (aprepitant) injectable emulsion. This approval has helped to bolster company footprints in U.S. market.
Collaboration, joint ventures and other strategies by the market players is enhancing the company impression in the cancer supportive care products market which also provides the benefit for organisation to improve their sales growth.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 DRUG TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 REGULATORY
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 GROWING CANCER BURDEN WORLDWIDE
5.1.2 INCREASING INITIATIVES BY GOVERNMENT AND OTHER HEALTHCARE ORGANIZATIONS
5.1.3 GROWING GERIATRIC POPULATION
5.1.4 RISING NUMBER OF PRODUCT APPROVAL
5.1.5 RISING EXPENDITURE ON HEALTHCARE
5.2 RESTRAINTS
5.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER SUPPORTIVE DRUGS
5.2.2 LACK OF EARLY DETECTION
5.3 OPPORTUNITIES
5.3.1 ACQUISITION AND AGREEMENT BY MAJOR PLAYERS
5.3.2 RISING PRODUCT LAUNCHES
5.3.3 GROWING R&D ACTIVITIES
5.4 CHALLENGES
5.4.1 STRINGENT REGULATION POLICY
5.4.2 PATENT EXPIRY OF DRUGS
6 COVID-19 IMPACT ON NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET
6.1 PRICE IMPACT
6.2 IMPACT ON SUPPLY CHAIN
6.3 IMPACT ON DEMAND
6.4 STRATEGIC DECISIONS FOR MANUFACTURERS
6.5 CONCLUSION
7 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE
7.1 OVERVIEW
7.2 GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS)
7.2.1 LONG ACTING FILGRASTIM
7.2.2 FILGRASTIM
7.2.3 LENOGRASTIM
7.3 ERYTHROPOIETIN STIMULATING AGENTS (ESA’S)
7.3.1 EPO-Α/Β
7.3.2 DPO
7.3.3 CERA
7.3.4 EPO-Κ
7.4 OPIOID ANALGESICS
7.4.1 FENTANYL
7.4.2 METHADONE
7.4.3 TRAMADOL
7.4.4 OTHERS
7.5 MONOCLONAL ANTIBODIES
7.6 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
7.6.1 OTC NSAIDS
7.6.1.1 ASPIRIN
7.6.1.2 IBUPROFEN
7.6.1.3 NAPROXEN SODIUM
7.6.2 PRESCRIPTION NSAIDS
7.6.2.1 CELECOXIB
7.6.2.2 DICLOFENAC
7.6.2.3 INDOMETHACIN
7.6.2.4 KETOROLAC
7.6.2.5 MELOXICAM
7.6.2.6 NABUMETONE
7.6.2.7 NAPROXEN
7.6.2.8 OXAPROZIN
7.6.2.9 PIROXICAM
7.6.2.10 SULINDAC
7.6.2.11 OTHERS
7.7 BISPHOSPHONATES
7.7.1 ZOLEDRONIC ACID OR ZOLEDRONATE
7.7.2 DISODIUM PAMIDRONATE
7.7.3 IBANDRONIC ACID OR IBANDRONATE
7.7.4 SODIUM CLODRONATE
7.8 ANTI-EMETICS
7.8.1 APREPITANT
7.8.2 DEXAMETHASONE
7.8.3 DOLASETRON
7.8.4 GRANISETRON
7.8.5 ONDANSETRON
7.8.6 PALONOSETRON
7.8.7 PROCHLORPERAZINE
7.8.8 ROLAPITANT
7.8.9 OTHERS
7.9 ANTIHISTAMINES
7.9.1 HYDROXYZINE
7.9.2 DIPHENHYDRAMINE
7.9.3 OTHERS
7.1 OTHERS
8 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE
8.1 OVERVIEW
8.2 BRANDED
8.2.1 NEULASTA
8.2.2 ARANESP
8.2.3 PROLIA
8.2.4 XGEVA
8.2.5 EPOGEN
8.2.6 EPREX
8.2.7 NEUPOGEN
8.2.8 OTHERS
8.3 GENERICS
9 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE
9.1 OVERVIEW
9.2 LUNG CANCER
9.3 BREAST CANCER
9.4 PROSTATE CANCER
9.5 LIVER CANCER
9.6 BLADDER CANCER
9.7 LEUKAEMIA
9.8 MELANOMA
9.9 OVARIAN CANCER
9.1 OTHER CANCERS
10 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.2.1 ACUTE CARE HOSPITALS
10.2.2 LONG-TERM CARE HOSPITALS
10.2.3 NURSING FACILITIES
10.3 CLINICS
10.4 HOSPITALS & ACADEMIC INSTITUTIONS
10.5 OTHERS
11 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 HOSPITAL PHARMACIES
11.3 RETAIL PHARMACIES
11.4 COMPOUNDING PHARMACIES
12 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY GEOGRAPHY
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT
15 COMPANY PROFILES
15.1 AMGEN INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 PFIZER INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 NOVARTIS AG
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 ACACIA PHARMA GROUP PLC
15.5.1 COMPANY SNAPSHOT
15.5.2 PRODUCT PORTFOLIO
15.5.3 RECENT DEVELOPMENTS
15.6 ACROTECH BIOPHARMA
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 APR
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 BAXTER
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 BAYER AG
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 F. HOFFMANN-LA ROCHE LTD
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENTS
15.11 HELSINN HEALTHCARE SA
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 HERON THERAPEUTICS, INC.
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.13 KYOWA KIRIN CO., LTD.
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENTS
15.15 MYLAN N.V.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENTS
15.16 OXFORD PHARMASCIENCE LTD
15.16.1 COMPANY SNAPSHOT
15.16.2 TECHNOLOGY PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 SPECTRUM PHARMACEUTICALS, INC.
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENTS
15.19 TERSERA THERAPEUTICS LLC
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
15.2 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
15.20.1 COMPANY SNAPSHOT
15.20.2 REVENUE ANALYSIS
15.20.3 PRODUCT PORTFOLIO
15.20.4 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
Tabellenverzeichnis
LIST OF TABLES
TABLE 1 NEW CANCER CASES, AGES 85+, IN THE U.S.
TABLE 2 MORTALITY DUE TO CANCER, AGES 85+, IN THE U.S.
TABLE 3 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE 2020-2028 (USD MILLION)
TABLE 4 NORTH AMERICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA MONOCLONAL ANTIBODIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA OTHERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE 2020-2028 (USD MILLION)
TABLE 23 NORTH AMERICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA GENERICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2020-2028 (USD MILLION)
TABLE 27 NORTH AMERICA LUNG CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA BREAST CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA PROSTATE CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA LIVER CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA BLADDER CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA LEUKAEMIA IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA MELANOMA IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA OVARIAN CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA OTHER CANCERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2020-2028 (USD MILLION)
TABLE 37 NORTH AMERICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA CLINICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA HOSPITALS & ACADEMIC INSTITUTIONS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA OTHERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
TABLE 43 NORTH AMERICA HOSPITAL PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA RETAIL PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA COMPOUNDING PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY COUNTRY 2019-2028 (USD MILLION)
TABLE 47 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 48 NORTH-AMERICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 49 NORTH-AMERICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 50 NORTH-AMERICA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 51 NORTH-AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 52 NORTH-AMERICA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 53 NORTH-AMERICA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 54 NORTH-AMERICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 55 NORTH-AMERICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 56 NORTH-AMERICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 57 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 NORTH-AMERICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 59 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 60 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 61 NORTH-AMERICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 63 U.S.CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 64 U.S.GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 65 U.S.OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 66 U.S. ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 67 U.S.NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 68 U.S. OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 69 U.S. PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 70 U.S. BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 71 U.S. ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 72 U.S. ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 73 U.S. CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 74 U.S. BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 U.S. CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 76 U.S. CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 77 U.S. HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 78 U.S. CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 79 CANADA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 80 CANADA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 81 CANADA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 82 CANADA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 83 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 84 CANADA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 85 CANADA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 86 CANADA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 87 CANADA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 88 CANADA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 89 CANADA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 CANADA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 CANADA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 92 CANADA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 93 CANADA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 94 CANADA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 MEXICO CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 96 MEXICO GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 97 MEXICO OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 98 MEXICO ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 99 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 100 MEXICO OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 101 MEXICO PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 102 MEXICO BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 103 MEXICO ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 104 MEXICO ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 105 MEXICO CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 106 MEXICO BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 MEXICO CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 108 MEXICO CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 109 MEXICO HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 110 MEXICO CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
Abbildungsverzeichnis
LIST OF FIGURES
FIGURE 1 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: SEGMENTATION
FIGURE 10 GROWING CANCER BUREN WORLDWIDE IS EXPECTED TO DRIVE THE NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET IN 2021 & 2028
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET
FIGURE 13 ESTIMATED NUMBER OF NEW CASES IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES
FIGURE 14 ESTIMATED AGE-STANDARDIZED INCIDENCE RATES (WORLD) IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES
FIGURE 15 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, 2020
FIGURE 16 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, 2020-2028 (USD MILLION)
FIGURE 17 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 18 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 19 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, 2020
FIGURE 20 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE 2020-2028 (USD MILLION)
FIGURE 21 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 22 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, 2020
FIGURE 24 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, 2020-2028 (USD MILLION)
FIGURE 25 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, CAGR (2021-2028)
FIGURE 26 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 27 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, 2020
FIGURE 28 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 29 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 30 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 32 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 33 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 34 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 35 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: SNAPSHOT (2020)
FIGURE 36 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2020)
FIGURE 37 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 38 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 39 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE (2021-2028)
FIGURE 40 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY SHARE 2020 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
